Cramer Remix: Buy into this weakness

Adam Jeffery | CNBC · CNBC

This is a sad market. Can someone please feed it some antidepressants? Anything that is positive is automatically interpreted as negative. But Jim Cramer refuses to look at it that way. He's got his rose-colored glasses on and is ready to do some buying into weakness.

Yes, oil prices are hitting dangerous prices. Yes, interest rates are low. As logical as it might seem to sell oil stocks and financials right now, Cramer warns against it.

"I think that when the market recovers from its bout of selling, there might not be all that much opportunity to get back in. You will have missed the pullback you have been waiting for," the "Mad Money" host said.

Just surrender. It is painful, but he would rather think about all of the buying opportunities that the weakness creates. Remember the Ebola scare? That was an opportunity.

So now the question becomes-are you using this pullback as an opportunity? Or are you panicking altogether? Cramer is standing his ground. He's not calling for people to get out just yet. The situation isn't as bad as most think.

Read More Cramer's warning: Don't miss the pullback opportunity

After such a hideous day on the averages, Cramer turned his attention to biotechs, which were one of the best performing sectors of 2014. It was crushed on Tuesday as well.

But here's the thing, this group wasn't just a winner in 2014. They have consistently done well for the past four years. Cramer expects that it will crush the S&P 500 in 2015 as well.

Thus, Cramer named the 10 best biotechs of last year that he has his eye on. They are OvaScience (OVAS), Agios Pharma (AGIO), BlueBird Bio (BLUE), Receptos (RCPT), TG Therapeutics (TGTX), Prosensa (RNA), Achillion Pharmaceuticals (ACHN), Amicus Therapeutics (FOLD), PTC Therapeutics (PTCT) and, last but not least, Esperion Therapeutics (ESPR).

Even though the cohort was smashed into smithereens on Tuesday, Cramer still thinks this group will roar into 2015.

"So many of these biotechs have transcended the one-drug-wonder mentality and are now developing technology platforms that could help them create many big drugs, which is why I think it makes sense to buy an Isis (ISIS) or an Agios (AGIO) into the weakness that we had today."


Now that Cramer has circled back to winning stocks, he has nominated the losers from last year. Cramer is interested to see if these dogs of the Dow that cost investors money last year, will turn things around this year.

First was McDonalds (MCD), followed by AT&T (NYSE:T), Boeing (BA), Verizon (VZ), Exxon Mobil (XOM), General Electric (GE), Chevron (CVX) and IBM (IBM).